|Epizyme Inc. Soars 26% Phase 1 of Tazemetostat|
|By Marilyn Mullen|
|Monday, 22 June 2015 14:03|
Biopharmaceutical firm Epizyme Inc. (NASDAQ:EPZM) has come out with results from Phase 1 of Tazemetostat, a first-in-class EZH2 inhibitor, demonstrating decent clinical activity when utilised as oral monotherapy in patients having advanced B-cell non-Hodgkin lymphomas as well as solid tumors.
In NHL, treating with Tazemetostat shows an encouraging profile with nine of 15 evaluable NHL patients getting a response which includes partial response in first treated patient with EZH2 tumor mutation.
The data has patients from dose escalation as well as dose expansion cohorts of phase 1 study besides those with food effects sub-study and was given by Vincent Ribrag, M.D., Institut Gustave Roussy, at 13th International Conference on Malignant Lymphoma.
Dr. Ribrag, opined that the depth of responses in NHL patients continue to impress besides the tolerability of Tazemetostat in the phase 1 study.
He added that there has been a noteworthy deepening of responses and first treated patient with EZH2 tumor mutation has witnessed partial response.
Peter Ho, M.D., Ph.D., Chief Development Officer, Epizyme, opined that the results show therapeutic potential of Tazemetostat in NHL with many patients getting durable remissions with time on treatment. He added that the firm was looking forward in exploring further the clinical utility of Tazemetostat in NHL in strong phase 2 development program.
NHL patients enrolled on study witnessed 85 percent of patients getting three or more prior therapies as well as 37 percent of patients getting more than five or more prior therapies. On the other hand, thirty-seven percent of patients were refractory to their previous regimen as well as 26 percent of patients getting previous autologous hematopoietic stem cell transplant.
Shares of the company are up 26% to $26.16.